TMEM41B Inhibitors
Chemical inhibitors of TMEM41B can influence the protein's function by targeting various aspects of lipid metabolism and transport. SR 59230A, a beta-3 adrenergic receptor antagonist, can impede the mobilization and metabolism of lipids. This action may affect the lipid-related functions of TMEM41B by altering the availability of lipids that TMEM41B would typically transport. Similarly, Triacsin C, which inhibits long-chain acyl-CoA synthetase, can disrupt lipid biosynthesis pathways by preventing the synthesis of acyl-CoA, a crucial substrate for lipid metabolism. This disruption can lead to a reduced lipid supply for TMEM41B to transport. ML236B, known as compactin or mevastatin, can inhibit HMG-CoA reductase, a key enzyme in cholesterol biosynthesis. This inhibition can reduce cholesterol levels, impacting the lipid composition of cellular membranes where TMEM41B operates. Filipin III can bind to sterols and disrupt lipid raft integrity, which can interfere with the function of TMEM41B in these membrane microdomains.
Further impacting the function of TMEM41B, Cerulenin can inhibit fatty acid synthase, leading to changes in lipid synthesis and potentially affecting the lipid transport role of TMEM41B by altering the lipid composition of membranes. PD 146176, a 15-lipoxygenase inhibitor, can alter fatty acid metabolism, which can change the lipid environment where TMEM41B functions. Betulinic Acid can inhibit sterol maturation, which can impair TMEM41B's role in vesicular trafficking of lipids. GW4869, by inhibiting neutral sphingomyelinase, can disrupt sphingolipid metabolism and subsequently influence the sphingolipid composition of cellular membranes, affecting TMEM41B's function. D609 targets phosphatidylcholine-specific phospholipase C and can alter phospholipid metabolism, potentially influencing TMEM41B's activity. Additionally, Perhexiline can affect fatty acid metabolism by inhibiting mitochondrial carnitine palmitoyltransferase-1, which can have repercussions for TMEM41B's lipid processing functions. Lastly, U18666A can inhibit cholesterol transport and biosynthesis, disrupting cholesterol dynamics and thus the lipid homeostasis required for TMEM41B's function in lipid transport and membrane organization.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triacsin C Solution in DMSO | 76896-80-5 | sc-200574 sc-200574A | 100 µg 1 mg | $187.00 $843.00 | 14 | |
This inhibitor targets long-chain acyl-CoA synthetase. By impeding the synthesis of acyl-CoA, Triacsin C can disrupt lipid biosynthesis and metabolic pathways, which could inhibit the lipid transport role of TMEM41B. | ||||||
Gossypol | 303-45-7 | sc-200501 sc-200501A | 25 mg 100 mg | $116.00 $230.00 | 12 | |
Also known as compactin or mevastatin, ML236B inhibits HMG-CoA reductase, potentially reducing the biosynthesis of cholesterol, a key component of cellular membranes where TMEM41B operates, thus indirectly inhibiting its function. | ||||||
Filipin III | 480-49-9 | sc-205323 sc-205323A | 500 µg 1 mg | $118.00 $148.00 | 26 | |
Filipin III binds to sterols in cell membranes and disrupts lipid raft integrity. Since TMEM41B is involved in lipid transport, disrupting membrane microdomains through Filipin III could inhibit TMEM41B's function in these regions. | ||||||
Cerulenin (synthetic) | 17397-89-6 | sc-200827 sc-200827A sc-200827B | 5 mg 10 mg 50 mg | $161.00 $312.00 $1210.00 | 9 | |
By inhibiting fatty acid synthase, Cerulenin affects lipid synthesis. As TMEM41B is associated with lipid transport, disrupting fatty acid synthesis can indirectly inhibit TMEM41B's function by affecting the lipid composition of membranes. | ||||||
Betulinic Acid | 472-15-1 | sc-200132 sc-200132A | 25 mg 100 mg | $117.00 $344.00 | 3 | |
This pentacyclic triterpenoid inhibits the maturation of sterols. Since TMEM41B is involved in vesicular trafficking of lipids, the inhibition of sterol maturation by Betulinic Acid could impair the normal function of TMEM41B. | ||||||
Elacridar | 143664-11-3 | sc-207613A sc-207613 sc-207613B sc-207613C sc-207613D | 5 mg 10 mg 50 mg 100 mg 1 g | $98.00 $113.00 $411.00 $525.00 $2606.00 | 19 | |
This compound is known to inhibit P-glycoprotein and Breast Cancer Resistance Protein, which are involved in drug efflux. By disrupting these transporters, Elacridar could indirectly inhibit TMEM41B's function in lipid transport due to altered intracellular drug concentrations. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $203.00 $611.00 | 24 | |
As an inhibitor of neutral sphingomyelinase, GW4869 disrupts sphingolipid metabolism. TMEM41B, with its role in lipid transport, could be functionally inhibited due to the altered sphingolipid composition in cellular membranes influenced by GW4869. | ||||||
D609 | 83373-60-8 | sc-201403 sc-201403A | 5 mg 25 mg | $189.00 $575.00 | 7 | |
Targeting phosphatidylcholine-specific phospholipase C, D609 can alter phospholipid metabolism. This alteration can indirectly inhibit TMEM41B's function by changing the lipid composition of the membranes where TMEM41B is active. | ||||||
rac Perhexiline Maleate | 6724-53-4 | sc-460183 | 10 mg | $188.00 | ||
Inhibitor of mitochondrial carnitine palmitoyltransferase-1, Perhexiline affects fatty acid metabolism. Since TMEM41B is involved in lipid processing, this disruption could inhibit TMEM41B's function. | ||||||
U 18666A | 3039-71-2 | sc-203306 sc-203306A | 10 mg 50 mg | $143.00 $510.00 | 2 | |
This agent is known to inhibit cholesterol transport and biosynthesis. The inhibition of cholesterol dynamics by U18666A could disrupt the lipid homeostasis required for TMEM41B's function in lipid transport and membrane organization. | ||||||